Page 4 - World Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

One Year Post-Launch of Argenx s Vyvgart for gMG, US Neurologists Confused on Best Approach to Treatment Dosing Schedules, According to Spherix Global Insights

/PRNewswire/ Argenx s launch of Vyvgart (efgartigimod) has been a success, with global first-year revenue of ~$400 million USD. As the second biologic.

Prnewswire argenxAlexion solirisGemma mcfaddenScott uphamGenentech enspryngCorporate communicationsSpherix networkSpherix global insightsLaunch dynamixMarket dynamixRealworld dynamixWorld dynamixGlobal insightsSenior insights directorSpherix global insight

Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights

/PRNewswire/ According to Biogen s earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third.

Gemma mcfaddenScott uphamCorporate communicationsSpherix networkRealtime dynamixSpherix global insightsPolpharma biologicLaunch dynamixRealworld dynamixTime dynamixWorld dynamixGlobal insightsGlobal insights contactsSenior insights directorSpherix global insightMedical pharmaceuticals

Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights

Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Gemma mcfaddenScott uphamCorporate communicationsSpherix networkRealtime dynamixSpherix global insightsPolpharma biologicLaunch dynamixRealworld dynamixTime dynamixWorld dynamixGlobal insightsGlobal insights contactsSenior insights directorNeurology scott uphamSpherix global insight

Switching Patterns Among Diabetic Macular Edema: Regeneron s Eylea Withstands the Evolving DME Switch Landscape

/PRNewswire/ The patient switch territory is evolving as more agents become available. Spherix s RealWorld Dynamix™ report allows for an inside look into.

Novartis beovuChrystal fergusonCoherus bioscience cimerliScott uphamGenentech vabysmoCorporate communicationsSpherix networkRealworld dynamixBiologic switchesDiabetic macular edemaCoherus bioscienceWorld dynamixGlobal insightsSpherix global insightsGlobal insights contactsInsights director

U S Nephrologists Report Mixed Reactions to the Approval of GSK s Jesduvroq® (daprodustat) for the Treatment of Anemia in Dialysis Patients, According to Spherix Global Insights

/PRNewswire/ Since 2017, Spherix Global Insights has been monitoring the U.S. renal anemia market landscape, capturing nephrologists perceptions and.

United statesAstrazeneca fibrogen astellasMeghan weissScott uphamCorporate communicationsUs food drug administrationSpherix networkSpherix global insightsDrug administrationSafety informationBlack boxRealtime dynamixRealworld dynamixComplete response lettersLaunch dynamixTime dynamix